Academic career Kubista began his academic career in 1991 as an assistant professor in the Department of Physical Chemistry at
Chalmers University of Technology. a company that develops real-time PCR tests for human
infectious diseases.
TATAA Biocenter In 2001, Kubista cofounded TATAA Biocenter, and Care Equity invested in
TATAA Biocenter. To facilitate the investment, a new holding company, Bioholdings LP, was established to acquire TATAA. During restructuring connected to TATAA’s
COVID-19 testing business, Kubista and his co-founders, advised by a law firm, carried out an upstream merger between two holding entities. This violated a clause in the agreement that prohibited share transfers without written consent. In June 2023, Kubista was dismissed as CEO and forfeited the founders' shares without compensation. Care Equity sued Kubista. As of October 2025, legal proceedings related to the merger dispute remain ongoing in the Swedish courts. Kubista also sued the law firm for negligent advice and damages.
Precision BioAnalytics In 2025 Kubista together with Jens Björkman, Robert Sjöback and Fredrik Adlercreutz founded Precision BioAnalytics, around a new preanalytical procedure that increases sensitivity and improves precision of the preanalytical process in molecular analysis.
Selected findings and publications Kubista has close to 300 publications. • Studied and identified
chromophores and a variety of dyes commonly used as biomolecule labels like: tryptophan,
DAPI,
fluorescein, thiazole orange, and BEBO. • Techniques for gene expression at the level of individual cells and subcellular compartments. • Discovered the Regeneration Initiating Cells (RICs) == References ==